Key terms

About TVTX

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest TVTX news

Mar 27 9:24am ET Travere downgraded to Neutral at Guggenheim on smaller role in IgAN space Mar 27 6:43am ET Travere Therapeutics downgraded to Neutral from Buy at Guggenheim Mar 13 9:55am ET Buy Rating Affirmed for Travere Therapeutics on Strong FILSPARI Data and Favorable Regulatory Outlook Mar 11 7:42am ET Travere Therapeutics submits sNDA for FILSPARI for IgAN Feb 27 11:50pm ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (MRNA) and Travere Therapeutics (TVTX) Feb 24 9:59am ET Travere’s Sparsentan Nears European Market Breakthrough Feb 23 10:35am ET Buy Rating Affirmed: Expanding Market Potential for Travere Therapeutics’ Sparsentan Feb 23 10:23am ET Travere Therapeutics price target lowered to $17 from $20 at H.C. Wainwright Feb 23 7:09am ET Travere , CSL Vifor announce Sparsentan received positive CHMP opinion Feb 23 5:14am ET Travere Therapeutics, CSL Vifor get CHMP recommendation for sparsentan approval Feb 21 1:01am ET New Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest? Feb 18 11:47pm ET Buy Rating Affirmed for Travere Therapeutics Amidst Strong Filspari Launch and Promising Growth Prospects Feb 16 5:40pm ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Travere Therapeutics (TVTX) and 10x Genomics (TXG) Feb 16 5:23pm ET Travere Therapeutics price target raised to $14 from $10 at Citi Feb 16 8:39am ET Wedbush Sticks to Their Buy Rating for Travere Therapeutics (TVTX) Feb 16 7:38am ET Piper Sandler Gives a Hold Rating to Travere Therapeutics (TVTX) Feb 16 6:58am ET Travere Therapeutics (TVTX) Gets a Buy from Barclays Feb 16 5:47am ET Travere Therapeutics: Hold Rating Amidst Filspari’s Steady Performance and Emerging Market Competition Feb 16 5:09am ET Bank of America Analyst Reaffirms Buy Rating on Travere Therapeutics Citing Strong Sales and Growth Potential Feb 15 8:40pm ET Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Travere Therapeutics (TVTX) and Grifols SA (GRFS) Feb 15 4:12pm ET Travere Therapeutics reports Q4 EPS (94c), consensus ($1.22) Jan 29 11:45am ET Strategic Partnerships and Regulatory Advancements Anchor Buy Rating for Travere Therapeutics Jan 26 3:11am ET Analysts Are Bullish on These Healthcare Stocks: Abbott Labs (ABT), Travere Therapeutics (TVTX) Jan 25 4:25pm ET Travere in $120M licensing deal with Renalys to develop sparsentan in Asia Jan 25 7:37am ET Travere Therapeutics price target raised to $15 from $12 at TD Cowen Jan 25 6:50am ET Analysts Are Bullish on These Healthcare Stocks: BeiGene (BGNE), Travere Therapeutics (TVTX) Jan 18 7:35am ET Travere Therapeutics price target raised to $11 from $10 at Piper Sandler Jan 11 1:27am ET Travere Therapeutics: A Strong Buy on Filspari’s Outperformance and Promising Market Prospects Jan 09 6:38am ET Bullish Outlook: Buy Rating on Travere Therapeutics Amidst Strong FILSPARI Sales and Promising Milestones Jan 08 7:41am ET Travere Therapeutics announces anticipated 2024 milestones Jan 08 7:38am ET Travere Therapeutics sees 2023 net product sales from cont. ops. $40M

No recent news articles are available for TVTX

No recent press releases are available for TVTX

TVTX Financials

1-year income & revenue

Key terms

TVTX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

TVTX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms